Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

Style Box ETF report for USMV

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.

Zacks Market Edge Highlights: Bank of America, Microsoft, Chevron, Merck and Marathon Digital

Bank of America, Microsoft, Chevron, Merck and Marathon Digital are part of the Zacks Market Edge blog.

Tracey Ryniec headshot

Advice for Long-Term Stock Investors

Thought long-term investing would be easy? Here's how to stay the course.

Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal

Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

Merck (MRK) closed at $110.45 in the latest trading session, marking a -1.6% move from the prior day.

Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?

Smart Beta ETF report for PWV

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

The Zacks Analyst Blog Highlights Home Depot, Merck, Bank of America, Elevance Health and ResMed

Home Depot, Merck, Bank of America, Elevance Health and ResMed are included in this Analyst Blog.

Merck (MRK) Gains But Lags Market: What You Should Know

In the latest trading session, Merck (MRK) closed at $110.81, marking a +0.39% move from the previous day.

Sheraz Mian headshot

Top Analyst Reports for Home Depot, Merck & Bank of America

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Merck & Co., Inc. (MRK) and Bank of America Corporation (BAC).

Moderna (MRNA) Reports 2023 Business View & Pipeline Updates

Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.

Here's Why Merck (MRK) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab

The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed at $111.14 in the latest trading session, marking a +0.17% move from the prior day.

Why Merck (MRK) is Poised to Beat Earnings Estimates Again

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sweta Killa headshot

Dow Jones Beats S&P 500 in 2022: 5 Hot Stocks

The Dow Jones fared as the best of the indexes and five stocks -- Chevron (CVX), Merck (MRK), Travelers (TRV), Amgen (AMGN), and Caterpillar (CAT) -- gained in double-digits in 2022.